Blackstone-backed HealthEdge is back in market, two years after shelving a partial sale effort, sources familiar tell Axios.
Why it matters: The payer tech company is targeting a full sale this time, at a $2 billion to $3 billion valuation — flat from 2022's failed auction, the sources say.
